CFH and ARMS2 Genetic Polymorphisms Predict Response to Antioxidants and Zinc in Patients with Age-related Macular Degeneration

      Objective

      The Age-Related Eye Disease Study (AREDS) demonstrated that antioxidant and zinc supplementation decreases progression to advanced age-related macular degeneration (AMD) in patients with moderate to severe disease. We evaluated the interaction of genetics and type of nutritional supplement on progression from moderate to advanced AMD.

      Design

      Genetic analysis of a randomized, prospective clinical trial.

      Participants

      White patients with AREDS category 3 AMD in 1 eye and AREDS categories 1 through 4 AMD in the fellow eye enrolled in the AREDS with available peripheral blood-derived DNA (995).

      Methods

      Subjects were evaluated for known AMD genetic risk markers and treatment category. The progression rate to advanced AMD was analyzed by genotypes and AREDS treatment group using Cox regression.

      Main Outcome Measures

      The effect of inherited gene polymorphisms on treatment group–specific rate of progression to advanced AMD.

      Results

      Over an average of 10.1 years, individuals with 1 or 2 complement factor H ( CFH) risk alleles derived maximum benefit from antioxidants alone. In these patients, the addition of zinc negated the benefits of antioxidants. Treatment with zinc and antioxidants was associated with a risk ratio (RR) of 1.83 with 2 CFH risk alleles ( P = 1.03E-02), compared with outcomes for patients without CFH risk alleles. Patients with age-related maculopathy sensitivity 2 ( ARMS2) risk alleles derived maximum benefit from zinc-containing regimens, with a deleterious response to antioxidants in the presence of ARMS2 risk alleles. Treatment with antioxidants was associated with an RR of 2.58 for those with 1 ARMS2 risk allele and 3.96 for those with 2 ARMS2 risk alleles ( P = 1.04E-6), compared with patients with no ARMS2 risk alleles. Individuals homozygous for CFH and ARMS2 risk alleles derived no benefit from any category of AREDS treatment.

      Conclusions

      Individuals with moderate AMD could benefit from pharmacogenomic selection of nutritional supplements. In this analysis, patients with no CFH risk alleles and with 1 or 2 ARMS2 risk alleles derived maximum benefit from zinc-only supplementation. Patients with one or two CFH risk alleles and no ARMS2 risk alleles derived maximum benefit from antioxidant-only supplementation; treatment with zinc was associated with increased progression to advanced AMD. These recommendations could lead to improved outcomes through genotype-directed therapy.

      Financial Disclosure(s)

      Proprietary or commercial disclosure may be found after the references.
      To read this article in full you will need to make a payment
      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Age-Related Eye Disease Study Research Group
        A randomized, placebo-controlled, clinical trial of highdose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
        Arch Ophthalmol. 2001; 119: 1417-1436
        • Nan R.
        • Gor J.
        • Lengyel I.
        • Perkins S.J.
        Uncontrolled zinc- and copper-induced oligomerisation of the human complement regulator factor H and its possible implications for function and disease.
        J Mol Biol. 2008; 384: 1341-1352
        • Perkins S.J.
        • Nan R.
        • Li K.
        • et al.
        Complement factor H-ligand interactions: self-association, multivalency and dissociation constants.
        Immunobiology. 2012; 217: 281-297
        • Nan R.
        • Farabella I.
        • Schumacher F.F.
        • et al.
        Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration.
        J Mol Biol. 2011; 408: 714-735
        • Calder P.C.
        • Albers R.
        • Antoine J.M.
        • et al.
        Inflammatory disease processes and interactions with nutrition.
        Br J Nutr. 2009; 101: S1-45
        • Fritsche L.G.
        • Loenhardt T.
        • Janssen A.
        • et al.
        Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA.
        Nat Genet. 2008; 40: 892-896
        • Zambon A.
        • Deeb S.S.
        • Pauletto P.
        • et al.
        Hepatic lipase: a marker for cardiovascular disease risk and response to therapy.
        Curr Opin Lipidol. 2003; 14: 179-189
        • Wang W.
        • Connor S.L.
        • Johnson E.J.
        • et al.
        Effect of dietary lutein and zeaxanthin on plasma carotenoids and their transport in lipoproteins in age-related macular degeneration.
        Am J Clin Nutr. 2007; 85: 762-769
        • Meyers K.J.
        • Johnson E.J.
        • Bernstein P.S.
        • et al.
        Genetic determinants of macular pigments in women of the Carotenoids in Age-Related Eye Disease Study.
        Invest Ophthalmol Vis Sci. 2013; 54: 2333-2345
        • Seddon J.M.
        • Ajani U.A.
        • Sperduto R.D.
        • et al.
        Eye Disease Case-Control Study Group. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration.
        JAMA. 1994; 272: 1413-1420
        • Yu Y.
        • Reynolds R.
        • Rosner B.
        • et al.
        Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models.
        Invest Ophthalmol Vis Sci. 2012; 53: 1548-1556
        • Li M.
        • Atmaca-Sonmez P.
        • Othman M.
        • et al.
        CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration.
        Nat Genet. 2006; 38: 1049-1054
        • Zar J.H.
        Biostatistical Analysis.
        4th ed. Prentice Hall, Upper Saddle River, NJ1999: 132-140
      1. Abdi H. Bonferroni test. In: Salkind, NJ, ed. Encyclopedia of Measurement and Statistics. vol. 1. Thousand Oaks, CA: Sage; 2007:103–107.

        • Age-Related Eye Disease Study Research Group
        A simplified severity scale for age-related macular degeneration: AREDS report no. 18.
        Arch Ophthalmol. 2005; 123: 1570-1574
        • Chew E.Y.
        • Clemons T.E.
        • Agron E.
        • Age-Related Eye Disease Study Research Group
        • et al.
        Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35.
        Ophthalmology. 2013; 120: 1604-1611
        • Klein M.L.
        • Francis P.J.
        • Rosner B.
        • et al.
        CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration.
        Ophthalmology. 2008; 115: 1019-1025
        • Perkins S.J.
        • Nealis A.S.
        • Sim R.B.
        Oligomeric domain structure of human complement factor H by X-ray and neutron solution scattering.
        Biochemistry. 1991; 30: 2847-2857
        • Okemefuna A.I.
        • Nan R.
        • Miller A.
        • et al.
        Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations.
        J Biol Chem. 2010; 285: 1053-1065
        • Bao B.
        • Prasad A.S.
        • Beck F.W.
        • et al.
        Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent.
        Am J Clin Nutr. 2010; 91: 1634-1641
        • Wallace D.C.
        A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine.
        Annu Rev Genet. 2005; 39: 359-407
        • Barron M.J.
        • Johnson M.A.
        • Andrews R.M.
        • et al.
        Mitochondrial abnormalities in ageing macular photoreceptors.
        Invest Ophthalmol Vis Sci. 2001; 42: 3016-3022
        • Kroemer G.
        • Reed J.C.
        Mitochondrial control of cell death.
        Nat Med. 2000; 6: 513-519
        • Lin M.T.
        • Beal M.F.
        Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.
        Nature. 2006; 443: 787-795
        • Beatty S.
        • Koh H.
        • Phil M.
        • et al.
        The role of oxidative stress in the pathogenesis of age-related macular degeneration.
        Surv Ophthalmol. 2000; 45: 115-134
        • McBride H.M.
        • Neuspiel M.
        • Wasiak S.
        Mitochondria: more than just a powerhouse.
        Curr Biol. 2006; 16: R551-R560
        • Age-Related Eye Disease Study 2 (AREDS2) Research Group
        Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.
        JAMA Ophthalmol. 2013; 131: 843-850

      Linked Article